^
Association details:
| Biomarker: | ALK fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Zykadia (ceritinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Clinical Research of Ceritinib Treating Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer With Brain Metastasis
Published date:
10/26/2021
Excerpt:
Ceritinib 450mg taken with taken with low-fat meal showed good efficacy and safety in crizotinib resistant patients with central nervous system metastasis, and also, it is effective in some cases with rare fusion of ALK.
Source:
Title:
A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed
Published date:
03/24/2021
Excerpt:
Of the 65 patients with ALK-positve NSCLC who underwent treatment failure of crizotinib, 43 (66.2%) received alectinib and 22 (33.8%) received ceritinib...The median follow-up duration was 16.8 months and 32.0 months in the alectinib and ceritinib groups, respectively....The tumor response was estimable in 63 patients (41 treated with alectinib and 22 treated with ceritinib), with the CR and PR being 2.4 and 70.8%,respectively, in the alectinib group and the PR being 50% in the ceritinib group.
DOI:
10.1186/s12885-021-08005-1
Source:
Title:
Ceritinib in Japanese patients with anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer: interim analysis results of a post-marketing surveillance study
Published date:
10/08/2020
Excerpt:
Meaningful efficacy was observed in both post-crizotinib and post-alectinib settings, with ORR of 29.55% (95% CI 20.29-40.22) and disease control rate of 53.41% (95% CI 42.46-64.12).
DOI:
10.1038/s41598-020-72863-1
